Business
Sernova to Acquire Cellular Local Immune Protection Technology Accelerating Expansion of its Regenerative Medicine Therapeutics Platform
(via TheNewswire) L ondon, Ontario - TheNewswire - June 8, 2020 - S...
About this update from Sernova Biotherapeutics Inc
[{"type":"text","content":"Sernova to Acquire Cellular Local Immune Protection Technology Accelerating Expansion of its Regenerative Medicine Therapeutics Platform(via TheNewswire)\n \n \nLondon, Ontario - TheNewswire - June 8, 2020 - Sernova Corp. (TSXV:SVA) (OTC:SEOVF)(FSE:PSH), a clinical-stage regenerative medicine therapeutics company, announced today its acquisition of an innovative cellular immune protection technology. This acquisition represents a strategic accelerator for expansion of Sernova's total regenerative medicine cell therapy therapeutics platform. \n\n\n \nSaid Dr. Philip Toleikis, President and CEO Sernova Corp., \"This is a game-changer for Sernova. We have strategically focused on adding local immune protection technologies to our portfolio as they represent the last essential pillar for our cell therapy therapeutics platform. This technology acquisition, in addition to our recently announced collaboration with AgeX Therapeutics, Inc. to use their UniverCyte(TM) gene-editing technology to protect cells, positions Sernova with multiple potential approaches to guard therapeutic cells within our Cell Pouch against host immune-response across multiple clinical applications.\" \n\n\n \nPursuant to an asset purchase agreement with Converge Biotech, Inc. (\"Converge\"), Sernova is acquiring all intellectual property associated with Converge's conformal coating cell encapsulation technology (\"Conformal Coating Technology\"), including issued patents, patent applications, and know-how. The transaction is expected to close by June 11, 2020.\n\n\n \n\"Conformal coating technology could be very synergistic with the Sernova Cell Pouch, as it could confer protection from the immune attack, decreasing or eliminating the need for immunosuppressive drugs. The minimal volume of the conformal capsules makes it possible to include immuno-protected insulin-producing cells in the Sernova Cell Pouch. If the combination of these technologies proves successful, it will represent an important step towards elimination of the need for immunosuppressive medications, bringing a functional cure closer to reality for patients suffering from this debilitating disease,\" said Dr. Camillo Ricordi, Stacy Joy Goodman Professor of Surgery and Chief, Division of Cellular Transplantation, Distinguished Professor of Medicine, Professor of Biomedical Engineering, Microbiol...